iShares U.S. Home Construction ETF (ITB)
- Previous Close
106.56 - Open
107.56 - Bid 108.50 x 1200
- Ask 110.00 x 800
- Day's Range
107.39 - 109.96 - 52 Week Range
71.22 - 116.34 - Volume
4,325,989 - Avg. Volume
1,905,786 - Net Assets 2.66B
- NAV 108.57
- PE Ratio (TTM) 12.06
- Yield 0.48%
- YTD Daily Total Return 6.97%
- Beta (5Y Monthly) 1.54
- Expense Ratio (net) 0.40%
The index measures the performance of the home construction sector of the U.S. equity market, as defined by the index provider. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. It is non-diversified.
iShares
Fund Family
Consumer Cyclical
Fund Category
2.66B
Net Assets
2006-05-01
Inception Date
Performance Overview: ITB
View MoreTrailing returns as of 7/12/2024. Category is Consumer Cyclical.
People Also Watch
Holdings: ITB
View MoreTop 10 Holdings (66.84% of Total Assets)
Sector Weightings
Recent News: ITB
View More
Research Reports: ITB
View MoreMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, online commerce set for acceleration, consolidation; the market may be missing changes afoot at Veolia; an overview of the moat ratings for big biotech firms; and Kraft Heinz, Tyson Foods, and Nutrien.
Biogen: Lowering Our Moat Rating to Narrow Based on MS Sales Pressure and Leqembi Uncertainty
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetRaising target price to $250
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in multiple sclerosis drugs and launched the first approved treatments for spinal muscular atrophy and Alzheimer's disease. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,570 people, and is a component of the S&P 500.
RatingPrice TargetBiogen Earnings: Encouraging Launches Point to Solid Growth Profile Beyond 2024
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice Target